{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:41:59Z","timestamp":1771623719048,"version":"3.50.1"},"reference-count":28,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,1,17]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is an aggressive subtype with high recurrence risk. The KEYNOTE-522 trial demonstrated improved pathological complete response (pCR) rates and survival outcomes with the addition of pembrolizumab to neoadjuvant chemotherapy. However, long-term immune-related adverse events (irAEs) remain a concern, particularly in curative settings. We report a case of a woman in her early 40s with node-positive TNBC who achieved a pCR following neoadjuvant chemoimmunotherapy. After completing adjuvant pembrolizumab, she developed acquired lipodystrophy, an under-recognised irAE, manifesting as progressive subcutaneous fat loss, dyslipidaemia, and hepatic steatosis. Histology demonstrated adipocyte necrosis with lymphohistiocytic infiltration. Corticosteroids stabilised progression but did not reverse changes. This case highlights the need for long-term surveillance of irAEs and raises important questions about immunotherapy de-escalation in patients achieving pCR, against a rapidly evolving systemic treatment landscape for TNBC.<\/jats:p>","DOI":"10.1136\/bcr-2025-269908","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:40:20Z","timestamp":1769697620000},"page":"e269908","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-induced lipodystrophy following pathological complete response in triple-negative breast cancer"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5266-777X","authenticated-orcid":false,"given":"Calvin R","family":"Flynn","sequence":"first","affiliation":[{"name":"Medical Oncology, Mater Misericordiae University Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0251-4967","authenticated-orcid":false,"given":"Clara","family":"Forrest","sequence":"additional","affiliation":[{"name":"Medical Oncology, Cork University Hospital, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orla","family":"O\u2019Mahony","sequence":"additional","affiliation":[{"name":"Pathology, Cork University Hospital, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seamus","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Medical Oncology, Cork University Hospital, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026012906400996000_19.1.e269908.1","doi-asserted-by":"crossref","first-page":"115545","DOI":"10.1016\/j.bcp.2023.115545","article-title":"Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies","volume":"212","author":"Karim","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"2026012906400996000_19.1.e269908.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549"},{"key":"2026012906400996000_19.1.e269908.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932"},{"key":"2026012906400996000_19.1.e269908.4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2466"},{"key":"2026012906400996000_19.1.e269908.5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamadermatol.2025.0359","article-title":"Immune Checkpoint Inhibitor-Induced Lipodystrophy","volume":"161","author":"Riganti","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026012906400996000_19.1.e269908.6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s42255-019-0095-y","article-title":"Leptin and the endocrine control of energy balance","volume":"1","author":"Friedman","year":"2019","journal-title":"Nat Metab"},{"key":"2026012906400996000_19.1.e269908.7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18124"},{"key":"2026012906400996000_19.1.e269908.8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/CMR.0000000000000660","article-title":"Acquired lipodystrophy associated with immune checkpoint inhibitors","volume":"30","author":"Gnanendran","year":"2020","journal-title":"Melanoma Res"},{"key":"2026012906400996000_19.1.e269908.9","first-page":"e40","article-title":"A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA","volume":"6","author":"Bedrose","year":"2020","journal-title":"AACE Clin Case Rep"},{"key":"2026012906400996000_19.1.e269908.10","doi-asserted-by":"crossref","DOI":"10.1210\/jcemcr\/luad025","article-title":"Marked Hypoleptinemia Precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy","volume":"1","author":"Dhanasekaran","year":"2023","journal-title":"JCEM Case Rep"},{"key":"2026012906400996000_19.1.e269908.11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02221"},{"key":"2026012906400996000_19.1.e269908.12","doi-asserted-by":"crossref","DOI":"10.31744\/einstein_journal\/2024RC1111","article-title":"Treatment of facial lipodystrophy induced by a biologic agent (IPD-1): a literature review","volume":"22","author":"Friedhofer","year":"2024","journal-title":"Einstein (Sao Paulo)"},{"key":"2026012906400996000_19.1.e269908.13","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2535"},{"key":"2026012906400996000_19.1.e269908.14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/CMR.0000000000000998","article-title":"Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature","volume":"35","author":"Marsiglio","year":"2025","journal-title":"Melanoma Res"},{"key":"2026012906400996000_19.1.e269908.15","first-page":"100332","article-title":"Acquired lipodystrophy following use of pembrolizumab","volume":"16","author":"Weitzen","year":"2024","journal-title":"Current Problems in Cancer: Case Reports"},{"key":"2026012906400996000_19.1.e269908.16","first-page":"1513","article-title":"Facial lipodystrophy after immunotherapy with Nivolumab","volume":"19","author":"Drexler","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026012906400996000_19.1.e269908.17","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.2169\/internalmedicine.5072-24","article-title":"Immune Checkpoint Inhibitor-induced Mass-forming Pancreatitis and Lipodystrophy: A Case Report and Review of the Literature","volume":"64","author":"Oi","year":"2025","journal-title":"Intern Med"},{"key":"2026012906400996000_19.1.e269908.18","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.24.00372","article-title":"Academic Uphill Battle to Personalize Treatment for Patients With Stage II\/III Triple-Negative Breast Cancer","volume":"42","author":"Kok","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026012906400996000_19.1.e269908.19","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s43018-025-00990-7","article-title":"The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types","volume":"6","author":"Awada","year":"2025","journal-title":"Nat Cancer"},{"key":"2026012906400996000_19.1.e269908.20","doi-asserted-by":"crossref","unstructured":"Kreutz-Rodrigues L , Cherukuri S , Rames JD , et al . Immune Checkpoint Inhibitors-Associated Generalized Lipodystrophy: Reconstructive Challenges of an Emerging and Distinct Form of Lipodystrophy. J Craniofac Surg 2024. doi:10.1097\/SCS.0000000000010409","DOI":"10.1097\/SCS.0000000000010409"},{"key":"2026012906400996000_19.1.e269908.21","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2217\/fon-2021-1647","article-title":"KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol"},{"key":"2026012906400996000_19.1.e269908.22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1362641","article-title":"Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis","volume":"14","author":"Caputo","year":"2024","journal-title":"Front Oncol"},{"key":"2026012906400996000_19.1.e269908.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"2026012906400996000_19.1.e269908.24","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28385","article-title":"Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer","volume":"10","author":"Schipilliti","year":"2024","journal-title":"Heliyon"},{"key":"2026012906400996000_19.1.e269908.25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/RLU.0000000000002862","article-title":"Nivolumab-Induced Subcutaneous Fat Necrosis: Another FDG-Avid Immune-Related Adverse Event","volume":"45","author":"Bhargava","year":"2020","journal-title":"Clin Nucl Med"},{"key":"2026012906400996000_19.1.e269908.26","doi-asserted-by":"crossref","unstructured":"Shah A , Rodriguez JPP . SUN-610 Acquired Generalized Lipodystrophy: A Rare Side Effect of PD1-Inhibitor Therapy. Journal of the Endocrine Society 2020;4. doi:10.1210\/jendso\/bvaa046.1234","DOI":"10.1210\/jendso\/bvaa046.1234"},{"key":"2026012906400996000_19.1.e269908.27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/jamadermatol.2021.0058","article-title":"Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma","volume":"157","author":"Pach","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026012906400996000_19.1.e269908.28","doi-asserted-by":"crossref","DOI":"10.1210\/jcemcr\/luaf023","article-title":"Acquired Generalized Lipodystrophy as an Adverse Event of Combined Immune Checkpoint Inhibitor Therapy","volume":"3","author":"Kennedy","year":"2025","journal-title":"JCEM Case Rep"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-269908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:40:25Z","timestamp":1769697625000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-269908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,29]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bcr-2025-269908"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-269908","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}